Clinical Trials Directory

Trials / Completed

CompletedNCT00208208

Geodon (Ziprasidone) for Posttraumatic Stress Disorder

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
80 (planned)
Sponsor
Creighton University · Academic / Other
Sex
All
Age
19 Years – 64 Years
Healthy volunteers
Accepted

Summary

Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).

Detailed description

PTSD is a common disorder with 10% lifetime prevalence among Americans. The major causes of PTSD are sexual assault, accidents, disasters Despite this public health burden, only two drugs, sertraline (Zoloft) and paroxetine (Paxil), are approved by the FDA for the treatment of PTSD. New options for the treatment of PTSD are much needed. Approximately half of patients with PTSD respond to Zoloft and Paxil. Many patients experience psychotic symptoms with PTSD, which may not respond to treatment to Zoloft and Paxil. Though classified as an anxiety disorder in the DSM-IV, PTSD is accompanied by psychotic symptoms in almost half of patients (Butler et al 1996; Hamner et al 1999, Lindley et al 2000). Also, PTSD has an extensive comorbidity with major depressive disorder (Davis et al 2000). While Geodon is approved by the FDA in the United States for the treatment of psychosis, it has not been evaluated for the treatment of PTSD . A clinical trial of Geodon in PTSD will help delineate the potential antidepressant spectrum of efficacy of Geodon as well as its anxiolytic profile.

Conditions

Interventions

TypeNameDescription
DRUGZiprasidone

Timeline

Start date
2002-12-01
Completion
2005-04-01
First posted
2005-09-21
Last updated
2006-09-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00208208. Inclusion in this directory is not an endorsement.